Kornmann O, Mucsi J, Kolosa N, et al. - Researchers tested low-dose IND (indacaterol acetate)/MF(mometasone furoate) 150/80 μg once daily (OD) vs MF 200 μg OD, in terms of efficacy and safety in adult and adolescent patients with inadequately controlled asthma in this phase III QUARTZ, which represents a multicentre, randomised, double-blind, double-dummy and parallel-group study. There were 802 eligible patients who were randomly assigned to receive either low-dose IND/MF 150/80 μg OD via Breezhaler or MF 200 μg OD via Twisthaler for 12 weeks. Trough forced expiratory volume in 1 s (FEV₁) was assessed as the primary endpoint, and Asthma Control Questionnaire (ACQ-7) treatment difference following 12-week therapy as key secondary endpoint. A significant improvement in trough FEV₁ and ACQ-7 was afforded by low-dose IND/MF vs MF at Week 12. Low-dose IND/MF also brought about improvements in all other secondary endpoints such as ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, assessed over 12-week therapy. The reported safety was comparable. Findings are suggestive of the potential of low-dose IND/MF 150/80 μg OD as a treatment option for adult and adolescent patients with inadequately controlled asthma and lend support to its use in these patients.